The decision to prescribe a compounded or brand-name glucagon-like peptide 1 (GLP-1) medication for obesity treatment was never simple, but recent developments have complicated it further.
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Continuing GLP-1 receptor agonist medications when undergoing an endoscopic procedure appeared safe in a meta-analysis.
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational ...
The use of GLP-1-agonists was associated with a significantly reduced risk of hospitalisation due to alcohol use disorder. Semaglutide was associated with a 36% lower risk, and liraglutide with a ...